Transforming Access to Rare Disease Treatments Through Collaboration

September 29, 2025 - 01:02

David Mitchell, PharmD, MBA, from UC Davis, emphasizes the pivotal role of collaboration between health systems and pharmaceutical manufacturers in enhancing patient access to therapies for rare diseases. As the landscape of healthcare continues to evolve, these partnerships are proving essential in overcoming the unique challenges faced by patients with rare conditions.

The synergy between health systems and industry players is fostering innovative approaches to treatment development and delivery. By sharing resources, knowledge, and expertise, these collaborations are streamlining the process of bringing new therapies to market. This is particularly crucial for rare diseases, where the patient population is often small, making it difficult for manufacturers to justify the investment in research and development.

Mitchell highlights that these partnerships not only improve access to cutting-edge treatments but also contribute to better patient outcomes. By working together, health systems and manufacturers can ensure that patients receive timely diagnoses and appropriate therapies, ultimately leading to enhanced quality of life for those affected by rare diseases.